Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors.
Hasegawa, M., Nishigaki, N., Washio, Y., Kano, K., Harris, P.A., Sato, H., Mori, I., West, R.I., Shibahara, M., Toyoda, H., Wang, L., Nolte, R.T., Veal, J.M., Cheung, M.(2007) J Med Chem 50: 4453-4470
- PubMed: 17676829 
- DOI: https://doi.org/10.1021/jm0611051
- Primary Citation of Related Structures:  
2OH4 - PubMed Abstract: 
We herein disclose a novel chemical series of benzimidazole-ureas as inhibitors of VEGFR-2 and TIE-2 kinase receptors, both of which are implicated in angiogenesis. Structure-activity relationship (SAR) studies elucidated a critical role for the N1 nitrogen of both the benzimidazole (segment E) and urea (segment B) moieties. The SAR results were also supported by the X-ray crystallographic elucidation of the role of the N1 nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme. The left side phenyl ring (segment A) occupies the backpocket where a 3-hydrophobic substituent was favored for TIE-2 activity.
Organizational Affiliation: 
Tsukuba Research Laboratories, GlaxoSmithKline K.K., 43 Wadai, Tsukuba, Ibaraki 300-4247, Japan. masaichi.hasegawa@gsk.com